疫苗市场按类型、产品类型、疫苗组合、疫苗分类、给药途径、剂量、年龄组和最终用户划分 - 2025-2030 年全球预测

预计2024年疫苗市值将达760.5亿美元，2025年将成长至818.7亿美元，复合年增长率为7.72%，到2030年将达到1188.5亿美元。

主要市场统计数据
基准年2024年	760.5亿美元
预计2025年	818.7亿美元
预测年份 2030	1188.5亿美元
复合年增长率（%）	7.72%

透过前所未有的科学突破和全球公共卫生合作，开启疫苗创新的新时代

疫苗是现代医学最重要的成就之一，它每年可防止数百万人死亡，并减轻全球疾病负担，从而改变公共卫生。近期的科学突破加快了疫苗研发的进程，使我们能够以前所未有的方式应对新出现的感染疾病威胁。本节将介绍在技术快速进步、监管格局不断变化以及全球需求不断演变的背景下，疫苗研究的背景。

识别疫苗研发和分发的根本变化，这些变化将即时重新定义全球预防性医疗保健

在科学创新与全球卫生需求融合的推动下，疫苗产业正经历根本性变革。其中最前沿的是传讯RNA技术的快速成熟，该技术已证明能够以前所未有的速度和精度产生标靶免疫。这促使许多开发商大力投资基于平台的方法，以实现针对不同病原体的模组化回应。

评估2025年美国新关税对疫苗供应供应链和产业动态的影响

美国将于2025年征收新关税，这给全球疫苗供应链带来了巨大压力。关键原料和疫苗成品成分的进口关税正在增加依赖跨境采购的製造商的生产成本。这些成本压力促使许多公司探索国内生产方案，并加速对本地生物技术丛集以及受託製造厂商的投资。

深入了解疫苗市场细分，包括产品类型、组合、剂量和年龄组

疫苗平台的考察揭示了该领域的异质性。灭活疫苗仍然是许多国家免疫计画的基石，而减毒活疫苗则继续为麻疹-腮腺炎-德国麻疹和日本脑炎等疾病提供持久免疫力。同时，传讯RNA疫苗的快速崛起引发了模式转移，利用基于核酸的递送系统，并针对更广泛的病原体。

分析美洲、中东和非洲以及亚太地区疫苗市场的区域差异，突显独特的机会和挑战

北美继续在疫苗研究和商业化领域发挥核心作用，并在该地区的生物技术中心投入了大量资金。美国和加拿大的监管机构已采用先进的框架，以促进快速核准并培育有利于创新的生态系统。拉丁美洲国家正在进行区域性生产合作，以减少对进口的依赖，并透过公共卫生措施提高疫苗接种率。

透过策略联盟推动疫苗创新和市场扩张的主要企业概况；产品平臺和投资重点

领先的生物技术和製药公司正日益加强合作，以提高研发和生产效率。知名疫苗製造商与专业生物技术公司之间的策略联盟正在促进下一代平台的开发。这些联盟通常将深厚的免疫学专业知识与先进的递送技术相结合，从而加速新型抗原转化为临床候选药物的影响。

产业领袖建议采取策略行动，应对不断变化的疫苗格局，加强供应链并加快发展路径

为了保持竞争力，产业领导者应透过整合灵活的生产模式，实现跨平台和跨剂型的多元化生产布局。采用模组化设施和一次性技术，能够在突发公共卫生事件中快速扩大规模，从而支援更广泛的产品系列，同时又不损害营运弹性。

疫苗市场分析所采用的调查方法的详细信息，包括数据收集、检验、三角测量和专家咨询

该研究框架整合了原始数据和二手数据研究方法，以确保全面覆盖并提供可靠的见解。原始数据透过访问顶尖免疫学家、製造专家和政策制定者收集，提供有关技术趋势、监管变化和市场驱动因素的第一手观点。除了这些定性资讯外，我们还利用同行评审期刊、行业出版物和官方卫生机构报告进行了二手资料研究，以检验新兴主题。

疫苗市场动态的关键发现和策略意义摘要，为相关人员在复杂的公共卫生挑战时代做出决策提供参考

这项分析表明，技术创新，尤其是传讯RNA和病毒载体平台，正在重新定义疫苗研发范式。这些进步与先进的监管途径和公私合营相辅相成，从而加快了临床进展并增强了生产韧性。这些因素共同作用，使我们能够更积极地应对紧迫的健康威胁。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 快速部署mRNA疫苗平台，用于下一代感染疾病预防
• 开发耐热疫苗製剂，实现全球超低温运输独立性
• 将人工智慧融入疫苗抗原设计和临床试验优化
• 通用型泛冠状病毒疫苗的出现，可对抗多种 SARS 相关株
• 扩大鼻腔和黏膜疫苗接种方法以提高免疫力
• 利用新抗原分析和免疫疗法开发个人化癌症疫苗
• 基于区块链的疫苗供应链追踪提高了透明度和信任度
• 公私合营促进低收入国家公平获得疫苗
• 全球资金激增推动偏远地区耐热疫苗的研发
• 采用新一代佐剂配方增强通用流感疫苗的效力

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第八章疫苗市场（按类型）

• 灭活疫苗
• 减毒活疫苗
• 传讯RNA疫苗
• 次单元、重组疫苗、多醣体疫苗和结合疫苗
• 类毒素疫苗
• 病毒载体疫苗

9. 疫苗市场（依产品类型）

• BCG
• COVID-19
• DPTa
• 甲型肝炎/B型肝炎
• HPV
• 流感
• 日本脑炎
• 麻疹、腮腺炎和德国麻疹(MMR)
• 轮状病毒

第十章 疫苗市场（依疫苗组合）

• 单价疫苗
• 多效价疫苗

第十一章 疫苗市场（依疫苗分类）

• 预防性疫苗
• 治疗性疫苗

第十二章疫苗市场（依接种途径）

• 肌肉注射
• 鼻内
• 口服
• 皮下

13. 疫苗市场（按剂量）

• 多剂量
• 单一剂量

第十四章 疫苗市场（依年龄层）

• 成人
• 老年人
• 孩子们
  • 婴儿
  • 婴儿

第十五章疫苗市场（依最终用户）

• 学术研究机构
• 医院和诊所
• 疫苗接种中心

第16章：美洲疫苗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

第17章：欧洲、中东和非洲疫苗市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

18. 亚太疫苗市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十九章 竞争态势

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Biological E. Limited
  • BioNTech SE
  • Blue Lake Biotechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac NV
  • Daiichi Sankyo Company, Limited.
  • Gennova Biopharmaceuticals Limited
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited

第20章 研究人工智慧

第21章 研究统计

第22章 研究联络人

第23章 研究报导

第24章 附录

The Vaccines Market was valued at USD 76.05 billion in 2024 and is projected to grow to USD 81.87 billion in 2025, with a CAGR of 7.72%, reaching USD 118.85 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 76.05 billion
Estimated Year [2025]	USD 81.87 billion
Forecast Year [2030]	USD 118.85 billion
CAGR (%)	7.72%

Pioneering the Next Era of Vaccine Innovation Through Unprecedented Scientific Breakthroughs and Global Collaboration in Public Health

Vaccines have emerged as one of the most significant triumphs in modern medicine, transforming public health by preventing millions of deaths annually and reducing disease burden across the globe. Recent years have witnessed extraordinary scientific breakthroughs that have accelerated vaccine development timelines, enabling unprecedented responses to emerging infectious threats. This section introduces the context of vaccine research in a landscape defined by rapid technological advances, shifting regulatory paradigms, and evolving global needs.

The integration of cutting-edge platforms such as messenger RNA and viral vectors has redefined the possibilities for preventive and even therapeutic immunizations. These innovations are complemented by advancements in adjuvant technology, antigen design, and delivery systems that optimize immune responses while minimizing adverse events. As a result, vaccine developers are exploring novel targets ranging from infectious diseases to oncology and chronic conditions, signaling a broader scope of applications than ever before.

Beyond the laboratory, collaboration between academic institutions, biotechnology firms, and governmental agencies has intensified. Public-private partnerships have streamlined clinical trial processes and bolstered manufacturing capacity, ensuring that supply chains remain resilient in the face of disruptions. Simultaneously, digital tools for data collection, analysis, and post-market safety monitoring are enhancing transparency and building public trust. This introduction sets the stage for an in-depth exploration of transformative shifts, regional dynamics, and strategic imperatives shaping the future of vaccines.

Identifying Fundamental Transformations in Vaccine Development and Distribution That Are Redefining Preventive Healthcare Worldwide in Real Time

The vaccine industry has undergone fundamental transformations driven by the convergence of scientific innovation and global health imperatives. At the forefront is the rapid maturation of messenger RNA technology, which has demonstrated the capacity to create targeted immunizations with unprecedented speed and precision. This has prompted many developers to invest heavily in platform-based approaches, enabling modular responses to a diversity of pathogens.

Equally transformative is the rise of flexible manufacturing paradigms. The adoption of modular bioprocessing units and single-use technologies has decentralized production, allowing facilities to pivot quickly in response to surges in demand. Concurrently, advanced cold chain solutions and real-time monitoring systems have mitigated logistical challenges, ensuring that vaccines maintain potency from site to site and reach communities in remote regions.

Regulatory landscapes have adapted accordingly, introducing accelerated pathways such as rolling reviews and conditional approvals to expedite access during public health emergencies. At the same time, emphasis on equity has grown, with global initiatives promoting tiered pricing, technology transfer agreements, and local manufacturing partnerships. These shifts reflect a broader transformation in which preventive healthcare is being reimagined as an integrated endeavor that extends from discovery science through distribution, laying the foundation for more agile and inclusive immunization strategies.

Public perception and demand are also shifting alongside these developments. Enhanced transparency in clinical data sharing, coupled with targeted education campaigns, is improving vaccine literacy and acceptance. This cultural evolution underscores the importance of aligning scientific progress with community engagement, ultimately reinforcing the resilience of immunization programs against emerging challenges, from novel pathogens to vaccine hesitancy.

Evaluating the Consequences of New Tariff Measures in the United States on Vaccine Accessibility Supply Chains and Industry Dynamics in 2025

In 2025, the imposition of new tariff measures by the United States has exerted significant pressure on global vaccine supply chains. Import duties applied to critical raw materials and finished vaccine components have increased production costs for manufacturers that rely on cross-border procurement. These cost pressures have prompted many firms to explore domestic manufacturing options, accelerating investments in local biotechnology clusters and contract development and manufacturing organizations.

The ripple effects extend beyond cost management. Suppliers in Asia-Pacific and Europe have reexamined their export strategies in response to changing trade equations, seeking alternative markets or negotiating revised supply agreements. At the same time, vaccine developers are reassessing pricing strategies and contractual terms to ensure continuity of supply for public health programs and private sector clients. This recalibration is reshaping procurement practices and influencing long-term strategic partnerships.

Policymakers have been compelled to navigate a delicate balance between safeguarding domestic industries and preserving access to essential immunizations. Collaborative dialogues between government agencies, industry associations, and international bodies have been vital in mitigating the risk of shortages. These engagements have helped establish exceptions for critical health commodities, underscoring the recognition of vaccines as strategic assets in national security and public welfare.

As a result, the vaccine ecosystem is evolving toward a hybrid model that blends localized production resilience with global distribution efficiencies. Although the immediate impact of trade measures has introduced complexity, the longer-term effect may be a more robust and diversified supply network capable of responding to emergent health threats with greater agility.

Unraveling Comprehensive Insights Across Vaccine Market Segmentation Including Type Product Combination Classification Administration Dosage and Age Group

The sector's heterogeneity becomes evident when examining vaccine platforms. Inactivated formulations remain a cornerstone in many national immunization programs, while live-attenuated vaccines continue to provide durable immunity against diseases such as measles-mumps-rubella and Japanese encephalitis. At the same time, the rapid ascendance of messenger RNA vaccines has introduced a paradigm shift, leveraging nucleic acid-based delivery systems to target a wider range of pathogens.

Within product segments, the COVID-19 vaccine category has catalyzed unprecedented attention to development speed and distribution networks, influencing the strategies for hepatitis and influenza immunizations. Vaccines designed for rotavirus and human papillomavirus underscore the expanding focus on preventive measures against chronic and oncogenic conditions. Mono-valent doses offer targeted protection, whereas multi-valent formulations deliver broader coverage, reducing the number of administrations required for comprehensive immunization schedules.

Classification-based insights reveal that preventive vaccines dominate market priorities, yet therapeutic vaccines targeting oncology and chronic diseases are gaining traction. Routes of administration further differentiate offerings, with intramuscular injections remaining prevalent and emerging interest in intranasal and oral delivery systems driven by ease of administration, patient compliance, and cold chain considerations. Multi-dose vials support mass immunization campaigns, while single-dose formats align with on-demand and travel medicine requirements.

Age group segmentation highlights distinctive requirements, with pediatric vaccines tailored to infants and toddlers under rigorous safety standards, whereas adult and geriatric programs emphasize booster schedules and combined formulations. Finally, end-user categories span academic and research institutes that pioneer initial development to hospitals, clinics, and dedicated vaccination centers that administer immunizations at scale. Together, these segmentation layers paint a nuanced portrait of the vaccine landscape, informing targeted strategies for product development and market entry.

Analyzing Regional Vaccine Market Variations Across Americas Europe Middle East Africa and Asia Pacific to Highlight Unique Opportunities and Challenges

The Americas continue to play a central role in vaccine research and commercialization, driven by substantial investment in biotech hubs across North America. Regulatory authorities in the United States and Canada have adopted progressive frameworks that facilitate expedited approvals, fostering an ecosystem conducive to innovation. Latin American nations have pursued regional manufacturing collaborations to reduce reliance on imports and enhance immunization coverage through public health initiatives.

Europe, Middle East, and Africa represent a mosaic of established markets and emerging economies. The European Union benefits from harmonized regulatory standards and robust manufacturing capacity, while nations across the Middle East are investing in domestic capabilities to address regional health priorities. Sub-Saharan Africa has seen renewed emphasis on vaccine equity, with international partnerships supporting cold chain infrastructure and local clinical trial networks aimed at combating endemic diseases.

In Asia-Pacific, dynamic growth is underpinned by a diverse array of stakeholders. Industrial powerhouses leverage advanced bioprocessing technologies to produce a significant share of global vaccine volumes, while emerging markets such as Southeast Asia increase immunization rates through government-driven programs. Collaboration between multinational corporations and local manufacturers is expanding capacity and tailoring vaccine portfolios to regional epidemiological needs. Collectively, this regional tapestry underscores the importance of context-specific approaches to optimize vaccine delivery and policy frameworks worldwide.

Profiling Leading Companies Driving Vaccine Innovation and Market Expansion Through Strategic Collaborations Product Pipelines and Investment Priorities

Major biotechnology and pharmaceutical companies have intensified collaboration efforts to enhance research and manufacturing efficiency. Strategic alliances between established vaccine producers and specialized biotechnology firms are fostering the development of next-generation platforms. These partnerships often combine deep immunology expertise with advanced delivery technologies, accelerating the translation of novel antigens into clinical candidates.

Companies with expansive product pipelines are diversifying their portfolios beyond traditional indications. While a handful of global leaders maintain broad franchises across influenza, hepatitis, and pediatric immunizations, emerging players are focusing on niche segments, including therapeutic vaccines for oncology and chronic infections. Investments in process development, high-throughput screening, and artificial intelligence-driven antigen design are positioning these firms to capture growth in both preventive and therapeutic domains.

On the manufacturing front, industry leaders are scaling up capacity through greenfield plants and capacity expansions in strategic locations. Advanced facilities equipped with continuous bioprocessing and digital quality management systems are becoming the norm, reducing time to market and ensuring regulatory compliance. At the same time, companies are forging collaborations with contract manufacturing organizations to gain flexibility and mitigate supply chain risk.

Financial commitment to research and development remains robust, with capital allocated toward platform innovation, adjuvant discovery, and novel delivery systems. This investment landscape is supported by venture capital activity and public funding initiatives aimed at building resilient vaccine ecosystems. Collectively, these corporate strategies illuminate the competitive dynamics and growth drivers shaping the future of the vaccine industry.

Recommending Strategic Actions for Industry Leaders to Navigate Evolving Vaccine Landscapes Enhance Supply Chains and Accelerate Development Pathways

To maintain a competitive edge, industry leaders should diversify manufacturing footprints by integrating flexible production models that can pivot between platforms and dosage forms. Embracing modular facilities and single-use technologies will enable rapid scale-up during public health emergencies and support a broader product portfolio without compromising operational agility.

Strengthening the upstream supply chain is equally critical. Establishing partnerships with raw material suppliers in key regions can buffer against trade disruptions and tariff implications. Long-term procurement agreements coupled with transparent forecasting practices will enhance supplier relationships and reduce lead times, ensuring consistent material availability for complex biologic processes.

Investment in digital end-to-end visibility solutions can optimize cold chain integrity and distribution efficiency. Real-time data analytics and blockchain-enabled tracking systems will improve traceability and compliance, reducing wastage and supporting regulatory reporting requirements. Furthermore, integrating digital platforms for patient engagement and adherence monitoring can enhance immunization coverage and post-market surveillance.

Collaborations between industry, academia, and government agencies should be reinforced to accelerate innovation pipelines. Joint research consortia and public funding mechanisms can de-risk early-stage development and foster knowledge exchange. Finally, proactive engagement with regulatory bodies to shape policies on accelerated approvals and standardized data requirements will facilitate smoother market entry and timely access to life-saving vaccines.

Detailing Research Methodology Employed in Vaccine Market Analysis Including Data Collection Validation Triangulation and Expert Consultations

The research framework integrates both primary and secondary methodologies to ensure comprehensive coverage and robust insights. Primary data was gathered through interviews with leading immunologists, manufacturing experts, and policy makers, providing first-hand perspectives on technological trends, regulatory shifts, and market drivers. These qualitative inputs were augmented by secondary research drawing on peer-reviewed journals, industry publications, and official health agency reports to validate emerging themes.

Data validation and triangulation processes were employed to cross-verify information from disparate sources. Quantitative data points were examined for consistency across multiple publications, while qualitative insights were compared against real-world case studies and clinical trial outcomes. This multi-dimensional approach enabled the identification of convergent patterns and the resolution of any anomalies.

Analytical frameworks such as SWOT analysis, PESTEL evaluation, and Porter's Five Forces were applied to structure the findings and uncover strategic implications. Regional segmentation and supply chain mapping exercises further contextualized the data, highlighting critical inflection points and potential bottlenecks. Attention to methodological transparency and reproducibility was maintained throughout the research lifecycle.

Continuous quality control measures were instituted, including peer reviews by external experts and rigorous editorial oversight, ensuring that insights are both reliable and actionable. This methodology provides a solid foundation for understanding the complexities of the vaccine market, guiding stakeholders through an evolving landscape shaped by innovation and policy dynamics.

Summarizing Key Findings and Strategic Implications of Vaccine Market Dynamics to Inform Stakeholder Decisions in an Era of Complex Public Health Challenges

The analysis reveals that technological innovations, notably messenger RNA and viral vector platforms, are redefining the vaccine development paradigm. These advances are complemented by progressive regulatory pathways and public-private collaborations that expedite clinical progression and bolster manufacturing resilience. Together, these elements are enabling a more proactive response to emergent health threats.

Trade policies and regional dynamics exert profound influence on supply chain configurations, necessitating strategic approaches to mitigate cost pressures while maintaining global access. The evolving segmentation landscape, encompassing diverse vaccine types, administration routes, and dosage formats, underscores the importance of tailored strategies that address distinct demographic and epidemiological requirements.

Leading companies are capitalizing on robust pipelines and strategic alliances to drive market expansion, while investment in advanced manufacturing and digital platforms enhances operational efficiency. Regional disparities between the Americas, Europe Middle East & Africa, and Asia-Pacific highlight the need for contextualized solutions to optimize distribution and policy frameworks.

Strategic imperatives for stakeholders include diversifying production capabilities, fortifying supply chain partnerships, and leveraging digital tools for end-to-end visibility. Collaborative research models and early engagement with regulatory bodies will further accelerate innovation trajectories. These insights provide a roadmap for decision-makers seeking to navigate a landscape defined by rapid change and high stakes in global public health.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Rapid adoption of mRNA vaccine platforms for next-generation infectious disease prevention
• 5.2. Development of thermostable vaccine formulations for ultra-cold chain independence globally
• 5.3. Integration of artificial intelligence in vaccine antigen design and clinical trial optimization
• 5.4. Emergence of universal pan-coronavirus vaccines to address multiple SARS-related strains
• 5.5. Expansion of intranasal and mucosal vaccine delivery methods for improved immunity
• 5.6. Growth of personalized cancer vaccines harnessing neoantigen profiling and immunotherapy
• 5.7. Blockchain-enabled vaccine supply chain tracking enhancing transparency and trust
• 5.8. Collaborative public-private initiatives driving equitable vaccine access in low-income nations
• 5.9. Surge in global funding fueling development of thermostable vaccines for remote regions
• 5.10. Adoption of next-generation adjuvant formulations to boost universal influenza vaccine efficacy

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Vaccines Market, by Type

• 8.1. Introduction
• 8.2. Inactivated Vaccines
• 8.3. Live-Attenuated Vaccines
• 8.4. Messenger RNA Vaccines
• 8.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
• 8.6. Toxoid Vaccines
• 8.7. Viral Vector Vaccines

9. Vaccines Market, by Product Type

• 9.1. Introduction
• 9.2. BCG
• 9.3. COVID-19
• 9.4. DPTa
• 9.5. Hepatitis A/Hepatitis B
• 9.6. HPV
• 9.7. Influenza
• 9.8. Japanese Encephalitis
• 9.9. Measles-Mumps-Rubella (MMR)
• 9.10. Rotavirus

10. Vaccines Market, by Vaccine Combination

• 10.1. Introduction
• 10.2. Mono-Valent Vaccines
• 10.3. Multi-Valent Vaccines

11. Vaccines Market, by Vaccine Classification

• 11.1. Introduction
• 11.2. Preventive Vaccines
• 11.3. Therapeutic Vaccines

12. Vaccines Market, by Route of Administration

• 12.1. Introduction
• 12.2. Intramuscular
• 12.3. Intranasal
• 12.4. Oral
• 12.5. Subcutaneous

13. Vaccines Market, by Dosage

• 13.1. Introduction
• 13.2. Multi Dose
• 13.3. Single Dose

14. Vaccines Market, by Age Group

• 14.1. Introduction
• 14.2. Adult
• 14.3. Geriatric
• 14.4. Pediatric
  • 14.4.1. Infants
  • 14.4.2. Toddlers

15. Vaccines Market, by End User

• 15.1. Introduction
• 15.2. Academic & Research Institutes
• 15.3. Hospitals & Clinics
• 15.4. Vaccination Centers

16. Americas Vaccines Market

• 16.1. Introduction
• 16.2. United States
• 16.3. Canada
• 16.4. Mexico
• 16.5. Brazil
• 16.6. Argentina

17. Europe, Middle East & Africa Vaccines Market

• 17.1. Introduction
• 17.2. United Kingdom
• 17.3. Germany
• 17.4. France
• 17.5. Russia
• 17.6. Italy
• 17.7. Spain
• 17.8. United Arab Emirates
• 17.9. Saudi Arabia
• 17.10. South Africa
• 17.11. Denmark
• 17.12. Netherlands
• 17.13. Qatar
• 17.14. Finland
• 17.15. Sweden
• 17.16. Nigeria
• 17.17. Egypt
• 17.18. Turkey
• 17.19. Israel
• 17.20. Norway
• 17.21. Poland
• 17.22. Switzerland

18. Asia-Pacific Vaccines Market

• 18.1. Introduction
• 18.2. China
• 18.3. India
• 18.4. Japan
• 18.5. Australia
• 18.6. South Korea
• 18.7. Indonesia
• 18.8. Thailand
• 18.9. Philippines
• 18.10. Malaysia
• 18.11. Singapore
• 18.12. Vietnam
• 18.13. Taiwan

19. Competitive Landscape

• 19.1. Market Share Analysis, 2024
• 19.2. FPNV Positioning Matrix, 2024
• 19.3. Competitive Analysis
  • 19.3.1. Abbott Laboratories
  • 19.3.2. Astellas Pharma Inc.
  • 19.3.3. AstraZeneca PLC
  • 19.3.4. Bavarian Nordic A/S
  • 19.3.5. Bharat Biotech Ltd.
  • 19.3.6. Biological E. Limited
  • 19.3.7. BioNTech SE
  • 19.3.8. Blue Lake Biotechnology
  • 19.3.9. Capricor Therapeutics, Inc.
  • 19.3.10. Chongqing Zhifei Biological Products Co., Ltd.
  • 19.3.11. CSL Limited
  • 19.3.12. CureVac N.V.
  • 19.3.13. Daiichi Sankyo Company, Limited.
  • 19.3.14. Gennova Biopharmaceuticals Limited
  • 19.3.15. GlaxoSmithKline PLC
  • 19.3.16. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 19.3.17. Incepta Pharmaceuticals Ltd.
  • 19.3.18. Inovio Pharmaceuticals, Inc.
  • 19.3.19. Johnson & Johnson Services, Inc.
  • 19.3.20. Merck & Co., Inc.
  • 19.3.21. Moderna, Inc.
  • 19.3.22. Novavax, Inc.
  • 19.3.23. Pfizer Inc.
  • 19.3.24. Sanofi S.A.
  • 19.3.25. Serum Institute of India Pvt. Ltd.
  • 19.3.26. Sinovac Biotech Ltd.
  • 19.3.27. Takeda Pharmaceutical Company Limited
  • 19.3.28. VBI Vaccines Inc.
  • 19.3.29. Versatope Therapeutics
  • 19.3.30. Zydus Lifesciences Limited

20. ResearchAI

21. ResearchStatistics

22. ResearchContacts

23. ResearchArticles

24. Appendix

LIST OF FIGURES

• FIGURE 1. VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2024 VS 2030 (%)
• FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
• FIGURE 18. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. GLOBAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 20. GLOBAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 24. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 27. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 28. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 29. VACCINES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 31. VACCINES MARKET: RESEARCHAI
• FIGURE 32. VACCINES MARKET: RESEARCHSTATISTICS
• FIGURE 33. VACCINES MARKET: RESEARCHCONTACTS
• FIGURE 34. VACCINES MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL VACCINES MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL VACCINES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL VACCINES MARKET SIZE, BY BCG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL VACCINES MARKET SIZE, BY BCG, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL VACCINES MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL VACCINES MARKET SIZE, BY COVID-19, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL VACCINES MARKET SIZE, BY DPTA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL VACCINES MARKET SIZE, BY DPTA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS A/HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS A/HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL VACCINES MARKET SIZE, BY HPV, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL VACCINES MARKET SIZE, BY HPV, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL VACCINES MARKET SIZE, BY MEASLES-MUMPS-RUBELLA (MMR), BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL VACCINES MARKET SIZE, BY MEASLES-MUMPS-RUBELLA (MMR), BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL VACCINES MARKET SIZE, BY MONO-VALENT VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL VACCINES MARKET SIZE, BY MONO-VALENT VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL VACCINES MARKET SIZE, BY MULTI-VALENT VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL VACCINES MARKET SIZE, BY MULTI-VALENT VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 85. GLOBAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 87. GLOBAL VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 89. GLOBAL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 91. GLOBAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 93. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 94. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 95. AMERICAS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 97. AMERICAS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 99. AMERICAS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 101. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 103. AMERICAS VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 105. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 107. AMERICAS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 108. AMERICAS VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 109. AMERICAS VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 111. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 113. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 114. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 115. UNITED STATES VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 116. UNITED STATES VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 117. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 118. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 119. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 120. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 121. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 122. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 123. UNITED STATES VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 124. UNITED STATES VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 125. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 126. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 127. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 128. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 129. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 130. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 131. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 132. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 133. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 134. CANADA VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 135. CANADA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 136. CANADA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 137. CANADA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 138. CANADA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 139. CANADA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 140. CANADA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 141. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 142. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 143. CANADA VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 144. CANADA VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 145. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 146. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 147. CANADA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 148. CANADA VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 149. CANADA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 150. CANADA VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 151. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 152. MEXICO VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 153. MEXICO VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 154. MEXICO VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 155. MEXICO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 156. MEXICO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 157. MEXICO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 158. MEXICO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 159. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 160. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 161. MEXICO VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 162. MEXICO VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 163. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 164. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 165. MEXICO VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 166. MEXICO VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 167. MEXICO VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 168. MEXICO VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 169. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 170. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 171. BRAZIL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 172. BRAZIL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 173. BRAZIL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 174. BRAZIL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 175. BRAZIL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 176. BRAZIL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 177. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 178. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 179. BRAZIL VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 180. BRAZIL VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 181. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 182. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 183. BRAZIL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 184. BRAZIL VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 185. BRAZIL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 186. BRAZIL VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 187. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 188. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 189. ARGENTINA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 190. ARGENTINA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 191. ARGENTINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 192. ARGENTINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 193. ARGENTINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 194. ARGENTINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 195. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 196. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 197. ARGENTINA VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 198. ARGENTINA VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 199. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 200. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 201. ARGENTINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 202. ARGENTINA VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 203. ARGENTINA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 204. ARGENTINA VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 225. UNITED KINGDOM VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 226. UNITED KINGDOM VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 227. UNITED KINGDOM VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 228. UNITED KINGDOM VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 230. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 232. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 234. UNITED KINGDOM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 236. UNITED KINGDOM VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 238. UNITED KINGDOM VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 240. UNITED KINGDOM VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. UNITED KINGDOM VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 243. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 244. GERMANY VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 245. GERMANY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 246. GERMANY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 247. GERMANY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 248. GERMANY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 249. GERMANY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 250. GERMANY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 251. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 252. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 253. GERMANY VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 254. GERMANY VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 255. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 257. GERMANY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 258. GERMANY VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 259. GERMANY VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 260. GERMANY VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 261. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 262. FRANCE VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 263. FRANCE VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 264. FRANCE VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 265. FRANCE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 266. FRANCE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 267. FRANCE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 268. FRANCE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 269. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 270. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 271. FRANCE VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 272. FRANCE VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 273. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 274. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 275. FRANCE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 276. FRANCE VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 277. FRANCE VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. FRANCE VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 279. RUSSIA VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 280. RUSSIA VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 281. RUSSIA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 282. RUSSIA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 283. RUSSIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 284. RUSSIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 285. RUSSIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 286. RUSSIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 287. RUSSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 288. RUSSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 289. RUSSIA VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 290. RUSSIA VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 291. RUSSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 292. RUSSIA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 293. RUSSIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 294. RUSSIA VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 295. RUSSIA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 296. RUSSIA VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 297. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 298. ITALY VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 299. ITALY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 300. ITALY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 301. ITALY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 302. ITALY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 303. ITALY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 304. ITALY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 305. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 306. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 307. ITALY VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 308. ITALY VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 309. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 310. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 311. ITALY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 312. ITALY VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 313. ITALY VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 314. ITALY VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 315. SPAIN VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 316. SPAIN VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 317. SPAIN VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 318. SPAIN VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 319. SPAIN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 320. SPAIN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 321. SPAIN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 322. SPAIN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 323. SPAIN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 324. SPAIN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 325. SPAIN VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 326. SPAIN VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 327. SPAIN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 328. SPAIN VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 329. SPAIN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 330. SPAIN VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 331. SPAIN VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 332. SPAIN VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 333. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 334. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 335. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 336. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 337. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 338. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 339. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 340. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 341. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 342. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 343. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 344. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 345. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 346. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 347. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 348. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 349. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 350. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 351. SAUDI ARABIA VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 352. SAUDI ARABIA VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 353. SAUDI ARABIA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 354. SAUDI ARABIA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 355. SAUDI ARABIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 356. SAUDI ARABIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 357. SAUDI ARABIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 358. SAUDI ARABIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 359. SAUDI ARABIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 360. SAUDI ARABIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 361. SAUDI ARABIA VACCINES MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
• TABLE 362. SAUDI ARABIA VACCINES MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
• TABLE 363. SAUDI ARABIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 364. SAUDI ARABIA VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 365. SAUDI ARABIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 366. SAUDI ARABIA VACCINES MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
• TABLE 367. SAUDI ARABIA VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 368. SAUDI ARABIA VACCINES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 369. SOUTH AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
• TABLE 370. SOUTH AFRICA VACCINES MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
• TABLE 371. SOUTH AFRICA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 372. SOUTH AFRICA VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 373. SOUTH AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2024 (USD MILLION)
• TABLE 374. SOUTH AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025-2030 (USD MILLION)
• TABLE 375. SOUTH AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2024 (USD MILLION)
• TABLE 376. SOUTH AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025-2030 (USD MILLION)
• TABLE 377. SOUTH AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 378. SOUTH AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 379. SOUTH AFRICA VACCINES MARKET SIZE, BY DO